Study summary
Early CAR-T results in MS: no new MRI lesions after the first month
57people treated, with no new MRI lesions after the first month
What was tested
CAR-T therapy, in which immune cells are engineered to remove B cells deeply in one treatment, in people with MS.
What they found
- Across 57 people treated, no new MRI lesions appeared after the first month.
- An off-the-shelf version from donor cells has first safety data in progressive MS.
- Follow-up is short, and CAR-T carries real risks including serious immune reactions.
What it means
A possible one-time reset of the immune system. Still experimental.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.